Today, we celebrate a milestone in our fight against the COVID-19 pandemic, with the commercial licensing of our strategic partner Sinopharm’s vaccine in China, the largest market in the world.
The same vaccine was officially registered by the UAE Ministry of Health and Prevention (MOHAP) on 9th December 2020, on the basis of Sinopharm interim analysis showing 86% efficacy in preventing COVID-19 in the Phase III trial volunteers. Today’s approval was based on updated Sinopharm interim results submitted in China showing 79.34% efficacy.
The efficacy variance in the two interim analysis reports is due to two factors – time period and case definition.
The analysis submitted to the UAE was in early December and based on the Food and Drug Administration (FDA) case definition, while in China it was submitted at the end of December and based on the Chinese Center for Drug Evaluation (CDE) case definition. The CDE defines COVID-19 case in more stringent terms than the FDA. Both reports are correct and valid.
Very importantly, the core results of the two interim analyses are consistent – the positive conversion rate is above 99% and the protection rate is 100% against moderate to severe cases.
In addition, the vaccine has established a robust safety profile throughout the large-scale global trials and widespread emergency use programs.
With the regulatory approvals now in place, we are working with our colleagues at Sinopharm and in other trial countries to publish the detailed results in peer reviewed journals, both domestically and internationally.
About G42 Healthcare:
G42 Healthcare, a subsidiary of Abu Dhabi-based Group 42 – a leading technology company, is committed to developing a world-class, sustainable healthcare sector in the UAE. At the forefront in the battle against COVID-19, G42 Healthcare has partnered with health authorities in Abu Dhabi and specialised medical facilities to establish a massive throughput testing laboratory in 14 days and contribute to the trial effort of the UAE.
G42 Healthcare uses its advanced AI techniques and vast computing resources to accelerate the detection of COVID-19, conduct research into new vaccines and drug therapies, and map trends in the outbreak including virus mutations. The company has also developed its PPE manufacturing capacity.